These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 31540690)
21. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis. Mak JP; Man WY; Ma HT; Poon RY Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733 [TBL] [Abstract][Full Text] [Related]
22. Cytokinetic effects of Wee1 disruption in pancreatic cancer. Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070 [TBL] [Abstract][Full Text] [Related]
23. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200 [No Abstract] [Full Text] [Related]
24. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
26. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954 [TBL] [Abstract][Full Text] [Related]
27. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. Que W; Chen J; Chuang M; Jiang D APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676 [TBL] [Abstract][Full Text] [Related]
28. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315 [TBL] [Abstract][Full Text] [Related]
29. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088 [TBL] [Abstract][Full Text] [Related]
30. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931 [TBL] [Abstract][Full Text] [Related]
31. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387 [TBL] [Abstract][Full Text] [Related]
32. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3. Lin L; Chen D; Xiang ZF; Pei RZ; Zhang PS; Liu XH; Du XH; Lu Y Cancer Biomark; 2017 Aug; 20(2):217-224. PubMed ID: 28869453 [TBL] [Abstract][Full Text] [Related]
33. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734 [TBL] [Abstract][Full Text] [Related]
34. Wee1 kinase as a target for cancer therapy. Do K; Doroshow JH; Kummar S Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427 [TBL] [Abstract][Full Text] [Related]
35. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072 [TBL] [Abstract][Full Text] [Related]
36. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331 [TBL] [Abstract][Full Text] [Related]
37. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
38. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib. Malek E; Driscoll JJ Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530 [TBL] [Abstract][Full Text] [Related]
40. Identification of DNA methylation-regulated WEE1 with potential implications in prognosis and immunotherapy for low-grade glioma. Zhong WJ; Zhang LZ; Yue F; Yuan L; Zhang Q; Li X; Lin L Cancer Biomark; 2024; 40(3-4):297-317. PubMed ID: 39213054 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]